Laboratory of Virology and Chemotherapy, KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Leuven, Belgium.
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Mol Cell Proteomics. 2021;20:100144. doi: 10.1016/j.mcpro.2021.100144. Epub 2021 Sep 2.
Cyclotriazadisulfonamide (CADA) inhibits the cotranslational translocation of type I integral membrane protein human CD4 (huCD4) across the endoplasmic reticulum in a signal peptide (SP)-dependent way. Previously, sortilin was identified as a secondary substrate for CADA but showed reduced CADA sensitivity as compared with huCD4. Here, we performed a quantitative proteomic study on the crude membrane fraction of human T-cells to analyze how many proteins are sensitive to CADA. To screen for these proteins, we employed stable isotope labeling by amino acids in cell culture technique in combination with quantitative MS on CADA-treated human T-lymphoid SUP-T1 cells expressing high levels of huCD4. In line with our previous reports, our current proteomic analysis (data available via ProteomeXchange with identifier PXD027712) demonstrated that only a very small subset of proteins is depleted by CADA. Our data also confirmed that cellular expression of both huCD4 and sortilin are affected by CADA treatment of SUP-T1 cells. Furthermore, three additional targets for CADA are identified, namely, endoplasmic reticulum lectin 1 (ERLEC1), inactive tyrosine-protein kinase 7 (PTK7), and DnaJ homolog subfamily C member 3 (DNAJC3). Western blot and flow cytometry analysis of ERLEC1, PTK7, and DNAJC3 protein expression validated susceptibility of these substrates to CADA, although with varying degrees of sensitivity. Additional cell-free in vitro translation/translocation data demonstrated that the new substrates for CADA carry cleavable SPs that are targets for the cotranslational translocation inhibition exerted by CADA. Thus, our quantitative proteomic analysis demonstrates that ERLEC1, PTK7, and DNAJC3 are validated additional substrates of CADA; however, huCD4 remains the most sensitive integral membrane protein for the endoplasmic reticulum translocation inhibitor CADA. Furthermore, to our knowledge, CADA is the first compound that specifically interferes with only a very small subset of SPs and does not affect signal anchor sequences.
环三嗪二磺酰胺(CADA)以信号肽(SP)依赖的方式抑制Ⅰ型跨膜蛋白人 CD4(huCD4)的共翻译易位穿过内质网。先前,分选蛋白被鉴定为 CADA 的次要底物,但与 huCD4 相比,CADA 的敏感性降低。在这里,我们对人 T 细胞的粗膜部分进行了定量蛋白质组学研究,以分析有多少蛋白质对 CADA 敏感。为了筛选这些蛋白质,我们在表达高水平 huCD4 的 CADA 处理的人 T 淋巴细胞系 SUP-T1 细胞中使用稳定同位素标记的氨基酸在细胞培养技术与 CADA 处理的定量 MS 相结合。与我们之前的报告一致,我们当前的蛋白质组学分析(可通过 ProteomeXchange 获得标识符 PXD027712)表明,只有一小部分蛋白质被 CADA 耗尽。我们的数据还证实,huCD4 和分选蛋白的细胞表达均受 SUP-T1 细胞中 CADA 处理的影响。此外,还鉴定出 CADA 的另外三个靶标,即内质网凝集素 1(ERLEC1)、无活性酪氨酸蛋白激酶 7(PTK7)和 DnaJ 同源亚家族 C 成员 3(DNAJC3)。ERLEC1、PTK7 和 DNAJC3 蛋白表达的 Western blot 和流式细胞术分析验证了这些底物对 CADA 的敏感性,尽管敏感性不同。额外的无细胞体外翻译/易位数据表明,CADA 的新底物携带可切割的 SP,是 CADA 发挥共翻译易位抑制作用的靶标。因此,我们的定量蛋白质组学分析表明,ERLEC1、PTK7 和 DNAJC3 是 CADA 的验证后的其他底物;然而,huCD4 仍然是内质网易位抑制剂 CADA 最敏感的跨膜蛋白。此外,据我们所知,CADA 是第一个特异性干扰一小部分 SP 而不影响信号锚序列的化合物。